Imagine trying to bake a complex cake but only finding out it's ruined after it comes out of the oven. This technology acts like a smart thermometer that tells you exactly how the ingredients are reacting while they are still cooking. It uses living cells as a biological alarm system to spot if viruses are active and healthy in real-time.
Viral vector production is prone to errors and lacks the capacity to meet commercial demand. Current quality control is often slow and cannot provide the real-time data needed for sustainable, decentralized manufacturing.
A biohybrid sensor platform using living cells and optical technology. Key deliverables include a functional platform model, a microfluidic prototype for sample injection, and 3D bioprinted swelling cages.
If you are a manufacturer dealing with high error rates in viral vector production — this project developed a biohybrid sensor that monitors virus activity in almost real-time. This reduces the risk of batch failure and ensures strict safety requirements are met.
If you are a producer dealing with the need for flexible, small-scale production units — this project developed a miniaturized detection platform. This allows for streamlined quality control in decentralized settings rather than relying on a single massive factory.
If you are a developer dealing with the difficulty of integrating biological components into hardware — this project developed 3D bioprinting of swelling cages for sensors. This provides a blueprint for creating bio-intelligent systems that combine technical and biological parts.
Based on available project data, specific pricing or implementation costs are not provided.
The project specifically targets the transformation of biomanufacturing and aims to demonstrate applicability in an industrial setting, particularly for small and decentralized processes.
Based on available project data, the specific licensing terms are not mentioned, though it involves a consortium of 10 partners including 7 industry members.
The system uses a microfluidic platform for semi-automated injection of samples, allowing for in-line monitoring and almost real-time analysis.
The project period runs from 2022-07-01 to 2026-06-30, suggesting the technology is currently in the development and testing phase.
The project is heavily industry-driven with a 70% industry ratio, comprising 7 companies including 4 SMEs. This strong commercial presence, led by Fraunhofer, suggests the technology is being developed with a clear focus on market viability and industrial application rather than purely academic research.
Contact Fraunhofer Gesellschaft zur Förderung der Angewandten Forschung EV
Contact us to explore licensing opportunities for bio-intelligent sensing.
